重组人血管内皮抑制素联合放疗或放化疗治疗局部晚期非小细胞肺癌的疗效与安全性:汇总分析
该汇总分析纳入7项研究共271例局部晚期非小细胞肺癌患者,评估重组人血管内皮抑制素联合放疗(ERT)或同步放化疗(ECRT)的疗效与安全性。总体中位无进展生存期11.3个月,中位总生存期18.9个月,客观缓解率77.2%;联合方案有效且耐受性良好,但需前瞻性随机对照试验进一步验证。
要点
- 总体中位PFS 11.3个月,ECRT组11.2个月,ERT组11.8个月。
- 总体中位OS 18.9个月,ORR 77.2%;ECRT组18.4个月/77.5%,ERT组19.6个月/76.1%。
- ≥3级不良事件以白细胞减少(总体35.5%)和中性粒细胞减少(27.8%)多见。
核心结论
- 重组人血管内皮抑制素联合放疗或同步放化疗治疗局部晚期非小细胞肺癌有效且耐受性良好,毒性较低。
- 结论需前瞻性随机对照试验进一步验证。
研究设计与样本
- 汇总分析,检索数据库文献,纳入评估内皮抑制素联合放疗(ERT)或同步放化疗(ECRT)治疗LA-NSCLC疗效与安全性的前瞻性或回顾性(含单臂)研究。
- 共纳入7项研究(6项前瞻性试验和1项回顾性研究),271例LA-NSCLC患者。
- 主要结局包括客观缓解率(ORR)、局部控制率(LCR)、总生存期(OS)、无进展生存期(PFS)和不良事件(AEs),并进行异质性、敏感性和发表偏倚检验。
主要发现
- 总体中位PFS为11.3个月,ECRT组为11.2个月,ERT组为11.8个月。
- 总体中位OS为18.9个月、ORR为77.2%;ECRT组分别为18.4个月和77.5%,ERT组分别为19.6个月和76.1%。
- 所有患者、ECRT组和ERT组的≥3级放射性肺炎发生率分别为10.9%、11.9%和9.4%。
- 所有患者、ECRT组和ERT组的≥3级放射性食管炎发生率分别为11.6%、12.2%和9.4%。
- 所有患者、ECRT组和ERT组的≥3级白细胞减少发生率分别为35.5%、43.4%和0,中性粒细胞减少分别为27.8%、40.7%和2.1%,贫血分别为10.5%、12.3%和2.1%。
临床怎么用
- 对局部晚期非小细胞肺癌,可考虑在内皮抑制素联合放疗或同步放化疗方案中评估疗效与安全性。
- 治疗中需重点监测≥3级血液学毒性(白细胞减少、中性粒细胞减少、贫血)及放射性肺炎、放射性食管炎。
局限性
- 纳入研究数量少(7项),仅1项为回顾性研究,证据级别有限。
- 需前瞻性随机对照试验进一步验证结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the efficacy and safety of recombinant human endostatin in combination with radiotherapy (RT) or concurrent chemoradiotherapy (CCRT) in patients with locally advanced non-small cell lung cancer (LA-NSCLC). METHODS: We searched eligible literature in available databases using combinations of the following search terms: lung cancer, endostatin or endostar, radiotherapy or radiation therapy or chemoradiotherapy. The inclusion criteria were: prospective or retrospective (including single-arm) studies that evaluated the efficacy and safety of endostatin plus radiotherapy (ERT) or concurrent chemoradiotherapy (ECRT) in patients with LA-NSCLC. Primary outcomes included the following: objective response rate (ORR), local control rates (LCR), overall survival (OS), progression-free survival (PFS), and adverse events (AEs). Tests of heterogeneity, sensitivity, and publication bias were performed. RESULTS: A total of 271 patients with LA-NSCLC from 7 studies were enrolled, including six prospective trials and one retrospective study. The pooled median PFS was 11.3 months overall, 11.2 months in the ECRT group, and 11.8 months in the ERT group. Pooled median OS and ORR were 18.9 months and 77.2% overall, 18.4 months and 77.5% in the ECRT group, and 19.6 months and 76.1% in the ERT group, respectively. The incidences of major grade ≥ 3 AEs for all patients, subgroups of ECRT and ERT were 10.9% vs 11.9% vs 9.4% for radiation pneumonitis, 11.6% vs 12.2% vs 9.4% for radiation esophagitis, 35.5% vs 43.4% vs 0 for leukopenia, 27.8% vs 40.7% vs 2.1% for neutropenia, and 10.5% vs 12.3% vs 2.1% for anemia. CONCLUSIONS: Combined endostatin with RT or CCRT is effective and well tolerated in treating LA-NSCLC, and less toxicities occur. Further validation through prospective randomized control trials is required.
引用
- Zhang SL, Han CB, Sun L, et al. Efficacy and safety of recombinant human endostatin combined with radiotherapy or chemoradiotherapy in patients with locally advanced non-small cell lung cancer: a pooled analysis. Radiat Oncol. 2020. PMID: 32831120. doi:10.1186/s13014-020-01646-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。